Mitsubishi UFJ Asset Management Co. Ltd. Boosts Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 23.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 8,204 shares of the company’s stock after buying an additional 1,553 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in Intellia Therapeutics were worth $242,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in NTLA. Barclays PLC grew its position in shares of Intellia Therapeutics by 15.0% during the 3rd quarter. Barclays PLC now owns 256,626 shares of the company’s stock valued at $8,115,000 after acquiring an additional 33,558 shares during the period. ARK Investment Management LLC increased its position in Intellia Therapeutics by 14.7% in the fourth quarter. ARK Investment Management LLC now owns 11,412,449 shares of the company’s stock worth $347,966,000 after buying an additional 1,463,820 shares in the last quarter. American Century Companies Inc. raised its stake in shares of Intellia Therapeutics by 5.9% in the third quarter. American Century Companies Inc. now owns 267,213 shares of the company’s stock worth $8,449,000 after buying an additional 14,863 shares during the period. Raymond James Financial Services Advisors Inc. raised its stake in shares of Intellia Therapeutics by 13.3% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 36,225 shares of the company’s stock worth $1,104,000 after buying an additional 4,255 shares during the period. Finally, Wellington Management Group LLP lifted its position in shares of Intellia Therapeutics by 1.4% during the 3rd quarter. Wellington Management Group LLP now owns 2,651,994 shares of the company’s stock valued at $83,856,000 after buying an additional 36,630 shares in the last quarter. 88.77% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Intellia Therapeutics news, EVP James Basta sold 2,297 shares of the company’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $32.99, for a total transaction of $75,778.03. Following the sale, the executive vice president now directly owns 81,571 shares in the company, valued at $2,691,027.29. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 3.00% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the stock. BMO Capital Markets raised their target price on shares of Intellia Therapeutics from $62.00 to $70.00 and gave the stock an “outperform” rating in a research note on Friday, May 10th. Wolfe Research assumed coverage on shares of Intellia Therapeutics in a research note on Thursday, February 15th. They set a “peer perform” rating on the stock. The Goldman Sachs Group downgraded shares of Intellia Therapeutics from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $136.00 to $32.00 in a report on Friday, February 23rd. Canaccord Genuity Group raised their price target on Intellia Therapeutics from $72.00 to $73.00 and gave the company a “buy” rating in a report on Friday, February 23rd. Finally, Citigroup dropped their price objective on Intellia Therapeutics from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Friday, May 10th. One research analyst has rated the stock with a sell rating, four have given a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $66.77.

Intellia Therapeutics Stock Performance

Shares of NTLA opened at $24.88 on Friday. The company’s fifty day moving average is $24.65 and its 200 day moving average is $27.21. Intellia Therapeutics, Inc. has a fifty-two week low of $19.37 and a fifty-two week high of $47.48.

Intellia Therapeutics (NASDAQ:NTLA) last posted its earnings results on Thursday, February 22nd. The company reported ($1.46) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.01. Intellia Therapeutics had a negative net margin of 893.34% and a negative return on equity of 45.35%. The firm had revenue of ($1.92) million for the quarter, compared to the consensus estimate of $15.10 million. During the same period in the previous year, the firm posted ($1.40) EPS. As a group, sell-side analysts anticipate that Intellia Therapeutics, Inc. will post -5.12 earnings per share for the current year.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.